Chronoscale Holdings Corp annual report, FY2018

Ekso Bionics Holdings, Inc. — FY2018 Form 10-K

Filing identity: The supplied filing is Ekso Bionics Holdings, Inc.’s annual report for the fiscal year ended December 31, 2018, filed February 28, 2019. This does not match the request metadata naming Chronoscale Holdings Corp or “2018 Q4”; the filing reports full-year results, not a standalone fourth quarter.

Business context

Ekso designs, develops, and sells wearable exoskeletons for medical rehabilitation and industrial applications. Its medical business centers on the Ekso GT; industrial products include EksoVest and EksoZeroG. The company reported two operating segments, EksoHealth and EksoWorks. Figures below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.

Financial performance and liquidity

MetricFY2018FY2017Change
Revenue$11.332$7.353+54%
Gross profit$4.309$2.069+108%
Gross margin38.0%28.1%+9.9 percentage points
Operating expenses$31.339$33.681−7%
Operating loss$(27.030)$(31.612)Loss narrowed
Net loss$(26.992)$(29.122)Loss narrowed
Basic and diluted loss per share$(0.44)$(0.82)—
Cash used in operating activities$(22.165)$(31.226)Cash use decreased

Medical revenue was $8.826 million, including $6.403 million of device revenue and $2.100 million of service, support, and rentals. Industrial revenue was $2.478 million. EksoHealth gross profit was $3.894 million; EksoWorks gross profit was $0.423 million.

Revenue growth reflected higher industrial device sales and medical rentals, as well as higher medical device volume and average selling prices. R&D expense fell 38% to $5.847 million, mainly reflecting lower employment costs following a 2017 workforce reduction. Sales and marketing expense rose 5% to $13.827 million; G&A rose 9% to $11.700 million. The 2018 net loss included a $1.063 million non-cash gain from revaluing warrant liabilities; the corresponding 2017 gain was $3.909 million.

At year-end, cash was $7.655 million, total assets $17.655 million, and total stockholders’ equity $2.728 million. Current assets were $14.967 million and current liabilities $10.132 million. Net debt carrying value was $4.981 million, including $2.333 million current and $2.648 million long-term. The term loan bears interest at 30-day U.S. LIBOR plus 5.41%, matures January 2021, and is secured by substantially all assets other than intellectual property. Total contractual obligations, including interest, leases, purchase obligations, and capital lease payments, were $8.962 million.

Cash declined from $27.813 million to $7.655 million during 2018. The loan covenant required $5.269 million of unrestricted cash at December 31, leaving estimated effective unrestricted cash of $2.386 million. Management said resources were expected to cover obligations only until late in the second quarter of 2019 and that significant additional financing was required. The auditor’s report highlighted substantial doubt about the company’s ability to continue as a going concern.

Material developments, outlook, and risks

  • In August 2018, Ekso established an at-the-market equity program of up to $25 million and sold approximately 2.0 million shares for net proceeds of $4.446 million during the year. Approximately $20.134 million of capacity remained at year-end. Through February 28, 2019, it sold a further 1.294 million shares for net proceeds of $2.328 million.
  • In January 2019, the company entered a China joint venture in which it owns 20%; partners own 80% and committed aggregate cash contributions of RMB 624 million. Ekso contributed specified Chinese patent rights and expects mid-single-digit royalties on covered product sales. A partner affiliate invested $5 million in Ekso in February 2019; a further $5 million investment was conditional on the JV’s first product shipment. The JV is not controlled by Ekso.
  • Management’s 2019 priorities included expanding U.S. rehabilitation adoption and clinical evidence, developing Ekso GT features and therapies, growing industrial partnerships, expanding in selected Asian markets, and reducing costs through the China JV. The filing provides no numerical revenue, earnings, or margin guidance.
  • Industrial demand indicators included expanded Ford EksoVest deployments across 15 plants in seven countries and pilot orders from two aerospace manufacturers. These are commercial developments, not quantified forecasts.
  • Key risks include continued losses and cash burn, reliance on new financing, possible dilution, covenant and debt repayment requirements, long hospital sales cycles, uncertain market adoption and reimbursement, clinical-evidence and regulatory risks, product safety/liability exposure, competition, supply-chain dependence, foreign-exchange exposure, and China JV governance and execution risks.
  • Senior management and sales turnover occurred during 2018 and early 2019. A securities class action related to previously disclosed internal-control weaknesses was dismissed with prejudice in December 2018; shareholder derivative litigation remained pending at the filing date. Management and the auditor reported effective internal control over financial reporting as of December 31, 2018, following remediation efforts.
  • The company reported one Ekso GT adverse-event report to the FDA since January 2018; analysis found no device malfunction. The filing also notes prior field actions and ongoing product warranty and service obligations.

Most important facts for investors to verify

  • Whether post-year-end equity proceeds and other financing were sufficient to extend liquidity beyond management’s late-Q2 2019 estimate, and whether debt cash covenants remained satisfied.
  • Actual cash burn, unrestricted cash, and the timing and terms of any additional equity, debt, or partner financing; consider potential dilution from the ATM program.
  • Whether revenue growth—especially medical rentals and industrial sales—translated into sustained gross-margin improvement and lower service costs.
  • Whether the China JV received its committed capital, began manufacturing and shipping, and delivered the expected investment, royalties, and cost benefits to Ekso.
  • Progress and results of clinical studies, reimbursement efforts, regulatory clearances, and conversion of industrial pilots into recurring orders.
  • Status and potential financial exposure of the pending derivative litigation, along with product warranty, safety, and other contingencies.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.